Do nonglycaemic effects such as weight loss account for HbA1c lowering with efpeglenatide?: Insights from the AMPLITUDE-O trial.
Ulagamadesan VenkatesanMu YangShun Fu LeeKelley R H BranchStephano Del PratoCarolyn Su Ping LamRenato D LopesRichard PratleyJulio RosenstockNaveed SattarPublished in: Diabetes, obesity & metabolism (2024)